Tacrolimus dose study in early kidney transplant patients
Part of Immune system & allergy, Infections, Kidney & urinary clinical trials.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant very recently (no more than 7 days ago).
- Your transplant team started you on tacrolimus, along with mycophenolate/mycophenolic acid or everolimus.
- You are expected to stay on tacrolimus for at least the first 4 years (no planned early switch to a different rejection medicine like belatacept).
- You can take part in genetic testing and will sign consent for it.
- If you can become pregnant, you must use effective birth control and agree to it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study helps doctors find the right dose of tacrolimus (a medicine that prevents organ rejection) for children who received a kidney transplant. By using math models and blood test results, the trial aims to make dosing more precise and safer.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
Hear when a new Kidney Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.